USE OF BIOMARKERS IN MONITORING OF TREATMENT OF ACUTE HEMATOGENOUS OSTEOMYELITIS IN CHILDREN

biomarkers, bone metabolism, collagen, acute hematogenous osteomyelitis, telopeptides.

Relevance. Today, acute hematogenous osteomyelitis (AHO) remains a serious problem in childhood. According to the WHO, the annual incidence of AHO among children varies from 2 to 13 cases per 100,000 population, depending on the region, age, and level of medical care. Bone collagen biomarkers represent a new and promising tool in the diagnosis and monitoring of bone pathologies in children.

The aim of the study was to determine the levels of bone type I collagen synthesis and degradation biomarkers (PINP and β-CrossLabs) in children with acute hematogenous osteomyelitis.